Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine

Introduction

Research

  1. HOME
  2. Introduction
  3. Research
  4. PSMA-PET clinical research in prostate cancer

2) Diagnostic PET/SPECT【Oncology PET】
PSMA-PET clinical research in prostate cancer

F-18 PSMA-1007 PET, which is a state-of-the-art diagnostic imaging for detecting prostate cancer recurrence and metastasis with high accuracy, was launched in September 2019 for the first time in Japan.
It has been found that PSMA-PET can detect recurrent / metastatic lesions which conventional diagnostic imaging (CT and bone scintigraphy) failed to detect.
The PSMA-PET agent (F-18 PSMA-1007 injection) has been successfully manufactured using a synthesizer (manufactured by Sumitomo Heavy Industries, Ltd.).
PSMA is also effective as a treatment target in prostate cancer, and labeling with a therapeutic nuclide can have a significant therapeutic effect on advanced cancer. It is expected to expand to treatment in Japan in the future.

F-18 PSMA-1007 PET / CT image of prostate cancer A dotted line cross section of whole body PET (right) is displayed on PET / CT (left). In addition to the right iliac metastasis (red arrow), small lymph node metastasis (yellow arrows) which is difficult to detect with conventional CT is depicted.
F-18 PSMA-1007 PET / CT image of prostate cancer
A dotted line cross section of whole body PET (right) is displayed on PET / CT (left). In addition to the right iliac metastasis (red arrow), small lymph node metastasis (yellow arrows) which is difficult to detect with conventional CT is depicted.